GRACE THERAPEUTICS INC (GRCE) Stock Analyst Earnings Estimates
NASDAQ:GRCE - Nasdaq - US00439U1043 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 200K | -100.00% | 10.26M | 45.9M 347.37% | 100.86M 119.74% | 122.58M 21.53% | 130.78M 6.69% | |||||||
| EBITDA YoY % growth | -31.34M -136.17% | -22.12M 29.42% | -9.8M 55.70% | N/A -56.53% | N/A -18.19% | N/A 37.36% | -17.034M -50.00% | -17.85M -4.79% | -9.486M 46.86% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.67M -119.35% | -24.44M 27.41% | -10.72M 56.14% | -13.543M -43.10% | -15.228M -18.97% | -12.342M 37.72% | -17.909M -57.55% | -17.213M 3.89% | -14.721M 14.48% | -708.456K 95.19% | 38.891M 5,589.55% | 57.411M 47.62% | 63.006M 9.75% | |
| Operating Margin | N/A | N/A | -5,360.00% | N/A | N/A | N/A | N/A | N/A | -143.48% | -1.54% | 38.56% | 46.84% | 48.18% | |
| EPS YoY % growth | -9.12 77.98% | N/A -142.72% | N/A | -0.67 | -2.69 -300.02% | -1.98 68.46% | -1.95 -53.11% | -0.84 35.29% | -0.58 31.24% | 0.51 188.14% | 1.65 223.78% | 2.34 42.00% | 2.60 10.85% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 39.35% | -0.24 25.82% | -0.50 -91.96% | -0.32 -416.20% | -0.26 -13.64% | -0.21 12.50% | -0.15 69.34% | -0.07 77.42% |
| Revenue Q2Q % growth | 918K | 1.836M | 3.57M | 5.406M | ||||
| EBITDA Q2Q % growth | -5.591M -12.68% | -6.29M -30.28% | -7.688M -107.84% | -7.269M -128.86% | -5.304M 5.14% | -3.264M 48.11% | -1.836M 76.12% | 816K 111.23% |
| EBIT Q2Q % growth | -5.1M -2.76% | -5.61M -16.13% | -7.569M -104.35% | -6.63M -108.29% | -5.304M -4.00% | -4.386M 21.82% | -3.162M 58.22% | -1.53M 76.92% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2025 Q2Q % growth | 0.10 155.56% | -0.57 | 0.67 | 117.45% |
| Q3 2025 Q2Q % growth | -0.26 13.04% | -0.44 | 0.18 | 40.72% |
| Q2 2025 Q2Q % growth | -0.33 -73.68% | -0.64 | 0.31 | 48.68% |
| Q1 2025 Q2Q % growth | -0.37 -202.29% | -0.35 | -0.02 | -6.26% |
| Q4 2024 Q2Q % growth | -0.18 95.38% | -0.36 | 0.18 | 49.58% |
| Q3 2024 Q2Q % growth | -0.30 44.63% | -0.32 | 0.02 | 5.54% |
| Q2 2024 Q2Q % growth | -0.19 | -0.11 | -0.08 | -69.34% |
| Q4 2023 Q2Q % growth | -3.90 -390.20% | -0.86 | -3.04 | -355.18% |
| Q3 2023 Q2Q % growth | -0.54 20.35% | -0.94 | 0.40 | 42.72% |
| Q3 2022 Q2Q % growth | -0.68 | -0.49 | -0.19 | -38.48% |
| Q2 2021 Q2Q % growth | -0.10 96.18% | -0.65 | 0.55 | 84.07% |
| Q1 2021 Q2Q % growth | -0.55 54.00% | -0.57 | 0.02 | 3.36% |
| Q4 2020 Q2Q % growth | 1.94 210.00% | -0.90 | 2.83 | 315.69% |
| Q2 2020 Q2Q % growth | -2.72 45.16% | -0.73 | -1.99 | -270.37% |
| Q1 2020 Q2Q % growth | -1.20 34.78% | -1.14 | -0.06 | -5.04% |
| Q4 2019 Q2Q % growth | -1.76 | -1.22 | -0.54 | -43.79% |
| Q3 2019 Q2Q % growth | -0.56 | -1.14 | 0.58 | 50.98% |
| Q2 2019 Q2Q % growth | -4.96 | -2.28 | -2.68 | -117.09% |
| Q1 2019 Q2Q % growth | -1.84 | -2.20 | 0.36 | 16.49% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 38.25% | 38.25% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |